CNS

Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson's Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Lunedì, Aprile 22, 2024
Doctor of Philosophy, Brain, Parkinson's disease, Mouse, Glucocerebrosidase, Poster, Abstract (summary), MD, Cell, Associate professor, STXBP1, AAV, CNS, Genetics, Liver, Gene, Society, Central nervous system, GBA, NHP, Annual general meeting, Baylor University, Vaccine

THOUSAND OAKS, Calif., April 22, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida"), a leading fully integrated targeted gene therapy company, developing treatments for rare and common diseases across all ages, today announced eight presentations – three oral presentations and five poster presentations – at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD and virtually.

Key Points: 
  • "We are excited to unveil our PD-GBA program and new data on our STXBP1 program as part of oral presentations at ASGCT," said Peter Anastasiou, Capsida's Chief Executive Officer.
  • "Both development candidates are IV-administered and achieve breakthrough levels of neuronal transduction throughout the brain, up to 70% in certain brain regions, while simultaneously detargeting the liver.
  • Data from the oral presentations are embargoed until 6:00 AM ET on the presentation day.
  • Presenter: Nicholas Flytzanis, Ph.D., Founder, Chief Research and Innovation Officer, Capsida

Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting

Retrieved on: 
Lunedì, Aprile 22, 2024
DRG, Heart, Traffic barrier, Computational science, Safety, Abstract (summary), Tropism, Cardiac muscle, MD, Structure, Diagram, Cell, BAG3, AAV, Skeletal muscle, CNS, Senior, Synthetic media, Liver, Gene, Society, ALS, Ataxin-2, BBB, Toxicity, Central nervous system, Messenger, Generative, Transcytosis, Annual general meeting, Therapy, Vaccine

Affinia's novel capsids have favorable manufacturing yields and levels of preexisting population immunity.

Key Points: 
  • Affinia's novel capsids have favorable manufacturing yields and levels of preexisting population immunity.
  • "We are excited to unveil data on our next-generation bespoke capsids that demonstrate robust cardiac transduction while detargeting the liver and DRG.
  • One oral presentation showcases data from Affinia's novel, BBB-penetrant AAV capsid with a potential therapeutic application to sporadic ALS.
  • The first poster showcases data that confirm the novel cardiotropic AAV capsid's safety and therapeutic efficacy in an animal model of cardiac dysfunction with a potential therapeutic application in genetic cardiomyopathies.

Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer

Retrieved on: 
Mercoledì, Aprile 17, 2024
Sequence, Doctor of Philosophy, Wilfrid Sellars, University, Genomics, Molecular genetics, GSK plc, Partnership, Shire (pharmaceutical company), CNS, Endo International, Villanova University, Marketing, MBA, Oxford Biomedica, Louisiana State University, Drug discovery, Pharmaceutical industry

BOSTON, April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.

Key Points: 
  • Dr. Rasty brings 25+ years of experience in R&D, strategy, commercial, BD&L, and corporate leadership as the company advances novel, best-in-class medicines to treat CNS disorders
    BOSTON, April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.
  • "Sam's expertise will fuel our business development and commercial strategies as we continue to progress our lead programs towards the clinic," said Alexandra Glucksmann, Ph.D., Chief Executive Officer of Sensorium.
  • Dr. Rasty was most recently Chief Executive Officer of Sequence Bio, a genomics and precision medicine company in Canada, President and Chief Executive Officer of PlateletBio, a pioneering cell therapy biotechnology company in the Boston area, and Board Director of Oxford Biomedica, a UK-based gene therapy company.
  • Previously, he served as Chief Operating Officer at Homology Medicines, a genetic medicines company that he helped launch in early 2016 and transform into a fully integrated public gene therapy and gene editing company.

AHP Backed Prolerity Clinical Research Appoints Drew Domescik as CFO

Retrieved on: 
Martedì, Aprile 16, 2024
CFO, Gastroenterology, DSM-IV codes, Investment, PPD, Cardiology, AHP, Tandem, CNS, Patient

NEW YORK, April 16, 2024 /PRNewswire/ -- Prolerity Clinical Research ("Prolerity), a clinical research site network and an AHP portfolio company, announced today that it has appointed Drew Domescik as Chief Financial Officer.

Key Points: 
  • NEW YORK, April 16, 2024 /PRNewswire/ -- Prolerity Clinical Research ("Prolerity), a clinical research site network and an AHP portfolio company, announced today that it has appointed Drew Domescik as Chief Financial Officer.
  • Prolerity currently owns and operates 11 research sites across Louisiana, Florida, New Jersey, and New York.
  • Prolerity is a research site network with therapeutic coverage across complex and challenging phase I-III trials, including gastroenterology, cardiology, CNS and metabolic disease.
  • Prolerity owns New Orleans based Tandem Clinical Research ("Tandem") which has become known for operating best-in-class research sites for NASH/NAFLD and neurodegenerative studies by demonstrating excellence in study feasibility, contracting, patient recruitment, patient retention, and quality.

XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube

Retrieved on: 
Giovedì, Aprile 11, 2024
FDA, ASM, Disorder, Mouth, Food, Water, Pharmacist, Seizure, CNS, Tablet, Patient, Epilepsy, Central nervous system, MBA, Pharmaceutical industry

"The approval addresses the needs of patients living with epilepsy who are currently taking, or who may benefit from starting XCOPRI, but are unable to swallow the tablets whole," said Louis Ferrari, BS, RPh, MBA, vice president, Medical Affairs at SK Life Science.

Key Points: 
  • "The approval addresses the needs of patients living with epilepsy who are currently taking, or who may benefit from starting XCOPRI, but are unable to swallow the tablets whole," said Louis Ferrari, BS, RPh, MBA, vice president, Medical Affairs at SK Life Science.
  • "In some patients, crushing tablets offers an additional option for dosing and administration by nasogastric tube.
  • This label update addresses an unmet need for this patient population and offers administration alternatives to the healthcare providers managing their care."
  • The FDA-approved label update considered the results of an open-label, randomized, single-center, 3-period, 6-sequence, balanced crossover study demonstrating bioequivalence between three administration routes including swallowing an intact tablet, as a crushed tablet suspended in water and taken orally, and as a crushed tablet suspended in water and administered via a nasogastric tube.

Corero Network Security Enters New Relationship with TierPoint

Retrieved on: 
Giovedì, Aprile 11, 2024
CNS, OTC, AIM, Partnership, Trust, CSO, Arms industry

MARLBOROUGH, Mass., April 11, 2024 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS, OTC: DDOSF), the distributed denial of service (DDoS) protection specialists, announces its new partnership with TierPoint.

Key Points: 
  • MARLBOROUGH, Mass., April 11, 2024 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS, OTC: DDOSF), the distributed denial of service (DDoS) protection specialists, announces its new partnership with TierPoint.
  • TierPoint has selected Corero Network Security for its next-generation DDoS defense infrastructure, underlining the critical need for cutting-edge, reliable cyber defense mechanisms in today's digital landscape.
  • Carl Herberger, CEO of Corero Network Security, expressed his enthusiasm about the new partnership, stating, "We are thrilled to welcome TierPoint to the Corero family.
  • The relationship with TierPoint signifies Corero's continued momentum in the cyber security space, further establishing its position as a preferred provider of innovative DDoS protection solutions for enterprises worldwide.

Cohen & Steers, Inc. to Release First Quarter 2024 Results on April 17, 2024

Retrieved on: 
Mercoledì, Aprile 10, 2024
CNS, Cohen & Steers, Internet access, Telephone, Webcast

NEW YORK, April 10, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release first quarter 2024 results after the market closes on Wednesday, April 17, 2024.

Key Points: 
  • NEW YORK, April 10, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release first quarter 2024 results after the market closes on Wednesday, April 17, 2024.
  • The earnings release and accompanying earnings presentation will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive."
  • The company will host a conference call on Thursday, April 18, 2024 at 10:00 a.m. (ET) with access available via webcast and telephone.
  • Internet access to the webcast, which includes audio (listen-only), will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations" under "Financials."

EQS-News: Newron presents 2023 financial results and provides 2024 outlook

Retrieved on: 
Mercoledì, Aprile 10, 2024
Psychosis, Schizophrenia, Clozapine, XETRA, Patient, CNS, Business development, Peripheral nervous system, Psychedelic literature, Safety, TRS, PANSS, EIB, Canadian International Council, Pharmaceutical industry

Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.

Key Points: 
  • Milan, Italy, March 19, 2024, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.
  • Results from the first 100 patients to complete six months (30 weeks) of treatment with evenamide were reported in January, followed by results in February 2023 from the same 100-person cohort at the one-year (52 weeks) timepoint.
  • These data were further strengthened, post-period in January 2024, with the final results from study 015 reviewing all study participants after one year of treatment.
  • Patient enrollment has completed and results from this study are expected in April 2024.

EQS-News:  Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million 

Retrieved on: 
Mercoledì, Aprile 10, 2024
EUR, Frankfurt Stock Exchange, XETRA, CFO, Patient, CNS, SIX Swiss Exchange, Peripheral nervous system, Security (finance)

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million

Key Points: 
  • Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
    The issuer is solely responsible for the content of this announcement.
  • Under the agreement, the fund subscribes to an initial 750,000 newly issued shares at a subscription price of EUR 7.33 per share, which corresponds to gross proceeds of approximately EUR 5.5 million.
  • In addition, the fund has a right to subscribe to an additional up to 1,300,000 newly issued shares until no later than January 31, 2025, at a subscription price to be calculated pursuant to an agreed formula.
  • “The investment by this specialist institutional fund is a validation of our strategy to develop innovative CNS therapies,” said Roberto Galli, CFO of Newron.

EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on: 
Mercoledì, Aprile 10, 2024
EIB, Peripheral nervous system, Patient, CNS, Schizophrenia, XETRA, European Investment Bank, BofA Securities, Pharmaceutical industry

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points: 
  • Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
  • The due dates for tranches four and five will stay unchanged.
  • On the amended tranches, Newron will start paying the agreed interest rates.
  • Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.